Viva Biotech and AlphaMa Reached Cooperation Agreement on IntelligentDEL (iDEL) Screening Platform

News

Home / News / Company News / Company News detail

Time: 2020-12-22

Source: Viva Biotech

[Abstract]:Viva Biotech will cooperate with AlphaMa to provide clients AI-based DNA coding compound library screening technology.

SHANGHAI, CHINA----Recently, Viva Biotech signed a new drug discovery technology cooperation agreement with AlphaMa Biotech Co., Ltd. (hereinafter referred to as "AlphaMa"). According to the agreement. Viva Biotech will cooperate with AlphaMa on innovative drug discovery technology to provide clients with the new generation of AI-based DNA coding compound library (Intelligent DEL, iDEL) screening technology platform for screening tumors and lead compounds for a series of specific targets in the field of neurological, autoimmune and other diseases......

Previous Page：Viva Biotech Awarded Next Page：Viva Biotech and Shanghai Biomedical Fund Announce the Cooperation to Jointly Build the Medical Innovation Achievement Transformation Platform

Back

Media contact: vivapr@vivabiotech.com